
## Halit Karaca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10466089/publications.pdf Version: 2024-02-01



ΗΛΙΙΤ ΚΛΡΛΟΛ

#	Article	IF	CITATIONS
1	The relationship between plasma hyaluronan levels and anthracycline-related cardiotoxicity in breast cancer patients. International Journal of Cardiology, 2016, 218, 246-251.	0.8	2
2	Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab. Breast, 2016, 25, 22-26.	0.9	17
3	ls Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?. Clinical Genitourinary Cancer, 2015, 13, 548-554.	0.9	10
4	Protective effects of spironolactone against anthracyclineâ€induced cardiomyopathy. European Journal of Heart Failure, 2015, 17, 81-89.	2.9	172
5	Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Medical Oncology, 2014, 31, 801.	1.2	52
6	Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. Medical Oncology, 2014, 31, 74.	1.2	8
7	Haematologic Parameters in Metastatic Colorectal Cancer Patients Treated with Capecitabine Combination Therapy. Asian Pacific Journal of Cancer Prevention, 2014, 15, 253-256.	0.5	14
8	Lack of Prognostic Value of Mean Corpuscular Volume with Capecitabine Therapy in Metastatic Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 2501-2504.	0.5	6
9	Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO). Anticancer Research, 2014, 34, 4463-70.	0.5	5
10	Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study. International Journal of Cardiology, 2013, 167, 2306-2310.	0.8	258
11	Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab. Onkologie, 2013, 36, 554-558.	1.1	2
12	Secondline Chemotherapy Versus Best Supportive Care in Patient with Malignant Pleural Mesothelioma: A Retrospective Study. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3887-3889.	0.5	5
13	Predictive significance of VEGF and HIF-1α expression in metastatic colorectal cancer patients receiving chemotherapy combined with bevacizumab Journal of Clinical Oncology, 2013, 31, e14672-e14672.	0.8	0
14	The effect of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy Journal of Clinical Oncology, 2013, 31, e20603-e20603.	0.8	0
15	Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 2145-2151.	1.2	10
16	Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer. Medical Oncology, 2012, 29, 3119-3124.	1.2	12